Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

2 results
12:00 AM, May 16, 2016  |  BC Week In Review | Company News  |  Other News

Epirus biosimilars, hematology, cancer news

preclinical compounds BOW080 , a biosimilar of Soliris eculizumab, to treat ultra-rare blood disorders and BOW070
12:00 AM, Aug 10, 2015  |  BC Week In Review | Company News  |  Deals

Epirus, Polpharma deal

Epirus partnered with Polpharma to develop and commercialize biosimilars BOW015 , BOW050 and BOW070 . BOW015 …
N.J.); BOW050 is a biosimilar of Humira adalimumab from AbbVie Inc. (NYSE:ABBV, Chicago, Ill.); and BOW070
retains U.S. rights to commercialize the biosimilar as well as rights to commercialize BOW050 and BOW070